Jon Quast
speaker
8,197 appearances
81 recordings
2 series
first heard Oct 2025
last heard 6d ago
Jon Quast’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 81 in all, peaking in Aug 2026 with 10.
Appearances
Stock remains in the doldrums.
I had high hopes when it acquired Celgene in late 2019, which seemed brilliant for its products and pipeline and got it cheap, but they've really struggled since then.
It seems.
Thoughts?
And of course, Drew here is referring to the $74 billion acquisition that happened in 2019.
So we're past the five-year mark and Bristol-Myers stock is up less than 1% since then.
Why hasn't this acquisition helped the stock?
So basically, patent issues, debt being very high, those things are kind of weighing the stock down.
The second part here of the question is, how would you compare them?
So Bristol-Myers Squibb, how would you compare them to Pfizer and other competitors?
So let me turn it to you here, Matt, because I know that you like dividends and we definitely, as Rachel brings up the dividend here, we want to get some more commentary and some thoughts here from a dividend perspective.
Both Bristol-Myers and Pfizer would be classified in the high yield category.
But is there one of these two that you would prefer as a dividend stock today?
Well, it's interesting you highlight one as being more aggressive than the other, because after the break, we're double dipping into the mailbag and talking to one of our youngest listeners.
You're listening to Motley Fool Hidden Gems Investing.
Welcome back to Motley Fool Hidden Gems Investing.
We do like to make you part of the conversation.
So if you have a stock or investing question for anyone on this show, we have different hosts throughout the week, but you can email us at podcastatfool.com and we'd love to read it on air.
We'd love to speak to it.
We do need you to keep it foolish.
Showing 3441–3460 of 8,197 · page 173 of 410
← Previous
Next →